KR20240082369A - 이미다조피리다진 il-17 억제제 화합물 - Google Patents

이미다조피리다진 il-17 억제제 화합물 Download PDF

Info

Publication number
KR20240082369A
KR20240082369A KR1020247013352A KR20247013352A KR20240082369A KR 20240082369 A KR20240082369 A KR 20240082369A KR 1020247013352 A KR1020247013352 A KR 1020247013352A KR 20247013352 A KR20247013352 A KR 20247013352A KR 20240082369 A KR20240082369 A KR 20240082369A
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
pharmaceutically acceptable
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247013352A
Other languages
English (en)
Korean (ko)
Inventor
딘 골든
스티븐 에이. 로스콧
스테판 맥카버
스티븐 피. 메두나
티모시 비. 로러
크리스틴 송
알렉산더 이. 발데스
동페이 우
시아오후아 슈에
루크 이. 한나
더글러스 씨. 비헤나
스티븐 디. 골드버그
Original Assignee
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔브이 filed Critical 얀센 파마슈티카 엔브이
Publication of KR20240082369A publication Critical patent/KR20240082369A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247013352A 2021-09-27 2022-09-26 이미다조피리다진 il-17 억제제 화합물 Pending KR20240082369A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163248566P 2021-09-27 2021-09-27
US63/248,566 2021-09-27
US202163273422P 2021-10-29 2021-10-29
US63/273,422 2021-10-29
US202263367546P 2022-07-01 2022-07-01
US63/367,546 2022-07-01
PCT/US2022/077001 WO2023049887A1 (en) 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds

Publications (1)

Publication Number Publication Date
KR20240082369A true KR20240082369A (ko) 2024-06-10

Family

ID=83692741

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013352A Pending KR20240082369A (ko) 2021-09-27 2022-09-26 이미다조피리다진 il-17 억제제 화합물

Country Status (16)

Country Link
US (2) US12173007B2 (https=)
EP (1) EP4408847A1 (https=)
JP (1) JP2024536869A (https=)
KR (1) KR20240082369A (https=)
AU (1) AU2022349687A1 (https=)
CA (1) CA3233408A1 (https=)
CL (1) CL2024000867A1 (https=)
CO (1) CO2024003723A2 (https=)
DO (1) DOP2024000051A (https=)
IL (1) IL311751A (https=)
JO (1) JOP20240059A1 (https=)
MX (1) MX2024003772A (https=)
PE (1) PE20240935A1 (https=)
TW (1) TW202330530A (https=)
UY (1) UY39958A (https=)
WO (1) WO2023049887A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311751A (en) 2021-09-27 2024-05-01 Janssen Pharmaceutica Nv IL-17 imidazopyridazine inhibitory compounds
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN120731202A (zh) * 2023-01-30 2025-09-30 戴斯阿尔法公司 基于苯并咪唑和氮杂-苯并咪唑的il-17a调节剂及其用途
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2024215597A1 (en) * 2023-04-11 2024-10-17 Dice Alpha, Inc. Substituted 6-imidazopyridazine il-17a modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752400B (zh) 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
PE20230469A1 (es) 2020-04-30 2023-03-14 Janssen Pharmaceutica Nv Imidazopiridazinas como moduladores de il-17
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
IL311751A (en) 2021-09-27 2024-05-01 Janssen Pharmaceutica Nv IL-17 imidazopyridazine inhibitory compounds
CN116143777A (zh) 2021-11-04 2023-05-23 四川海思科制药有限公司 一种可抑制il-17a的杂环化合物及其用途

Also Published As

Publication number Publication date
US20230143050A1 (en) 2023-05-11
CL2024000867A1 (es) 2024-09-23
CO2024003723A2 (es) 2024-04-18
WO2023049887A1 (en) 2023-03-30
AU2022349687A1 (en) 2024-05-16
IL311751A (en) 2024-05-01
EP4408847A1 (en) 2024-08-07
PE20240935A1 (es) 2024-04-30
CA3233408A1 (en) 2023-03-30
MX2024003772A (es) 2024-06-19
US12173007B2 (en) 2024-12-24
US20250109137A1 (en) 2025-04-03
TW202330530A (zh) 2023-08-01
JOP20240059A1 (ar) 2024-03-26
JP2024536869A (ja) 2024-10-08
DOP2024000051A (es) 2024-11-15
UY39958A (es) 2023-04-28

Similar Documents

Publication Publication Date Title
KR20240082369A (ko) 이미다조피리다진 il-17 억제제 화합물
CN107949559B (zh) 作为irak4调节剂的双环稠合杂芳基或芳基化合物
CN106458912B (zh) 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途
AU2014358792B2 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
JP6641373B2 (ja) ヤヌスキナーゼ阻害薬としての４，６−置換−ピラゾロ［１，５−ａ］ピラジン
TWI792158B (zh) 嘧啶酪氨酸激酶抑制劑
TW202233635A (zh) 囊腫纖維化跨膜傳導調節蛋白之調節劑
JP2020143162A (ja) キナーゼ阻害剤としてのピラゾロピリミジン誘導体
JP2021535118A (ja) ＫＥＡＰ１−Ｎｒｆ２タンパク質−タンパク質相互作用の阻害剤
RU2764980C2 (ru) Бициклические амины в качестве новых ингибиторов jak-киназы
KR20240082371A (ko) 이미다조피리다진 il-17 억제제 화합물
WO2024157205A1 (en) 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
EP3576743A1 (en) 5-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-5-AZASPIRO[2.5]OCTANE-8-CARBOXYLIC ACID DERIVATIVES AS NOVEL JAK KINASE INHIBITORS
JP7627269B2 (ja) ＲＯＲγｔ阻害剤、その製造方法及び使用
EA049269B1 (ru) Соединения ингибиторов il-17 на основе имидазопиридазина
CN118317962A (zh) 咪唑并哒嗪il-17抑制剂化合物
US20250320213A1 (en) Nitrogen-Containing Heterocyclic Compounds
KR20260023036A (ko) 암 치료를 위한 smarca2 분해 protac으로서의 3-[3-아미노-6-(2-하이드록시페닐)피리다진-4-일]-3,8-디아자비사이클로[3.2.1]옥탄 유도체

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000